Various publications attempt to correlate vitreal levels of VEGF to different clinical features in patients with PDR. Our findings suggest that the studies based on ELISA assessment of VEGF in the vitreous should be critically evaluated for a better understanding of the mechanism of PDR. In addition, novel strategies aimed at unmasking vitreal VEGF may increase the potency and efficacy of VEGF blockers, with therapeutic implications for patients with PDR.
Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey?
Rezzola, SaraWriting – Review & Editing
;Nawaz, Mohd IWriting – Original Draft Preparation
;Cancarini, AnnaMembro del Collaboration Group
;Semeraro, FrancescoFunding Acquisition
;Presta, Marco
Project Administration
2019-01-01
Abstract
Various publications attempt to correlate vitreal levels of VEGF to different clinical features in patients with PDR. Our findings suggest that the studies based on ELISA assessment of VEGF in the vitreous should be critically evaluated for a better understanding of the mechanism of PDR. In addition, novel strategies aimed at unmasking vitreal VEGF may increase the potency and efficacy of VEGF blockers, with therapeutic implications for patients with PDR.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Diabetes Care 2019.pdf
gestori archivio
Descrizione: Diabetes Care 2019
Tipologia:
Full Text
Licenza:
DRM non definito
Dimensione
638.26 kB
Formato
Adobe PDF
|
638.26 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
